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Abstract
Background The Tet-Off system uses a tetracycline-controlled transactiva-
tor protein (tTA) and a tetracycline-responsive promoter element (TRE)
to regulate expression of a target gene. This system can be used to
achieve regulatable transgene expression in speciﬁc cell types by employ-
ing a cell-speciﬁc promoter to drive tTA expression. Wide applications of
this attractive approach are, however, hindered by relatively weak tran-
scriptional activity of most cell-speciﬁc promoters. We report here the
feasibility of using a transcriptional ampliﬁcation strategy to overcome the
problem.
Methods and results In the developed cell-type-speciﬁc, Tet-inducible
lentiviral system, two distinct cellular promoters were tested, a human
synapsin-1 promoter for neurons and a compact glial ﬁbrillary acidic
protein promoter for astroglial cells. Lentiviral vectors were constructed
that contained two copies of one or the other of these two promoters.
One copy was used to drive the expression of a chimeric transactivator
consisting of a part of the transcriptional activation domain of the NF-κB
p65 protein fused to the DNA-binding domain of the yeast GAL4 protein.
The second copy of the cell-speciﬁc promoter was modiﬁed by introduction
of the GAL4 binding sequences at its 5  end. This copy was used to
drive expression of tTA. A gene encoding a red ﬂuorescent protein was
cloned into another lentiviral vector under transcriptional control of TRE.
Co-transduction with the two types of viral vectors provided doxycycline-
regulated transgene expression in a neuron- or astrocyte-speciﬁc manner.
Compared to control viruses without transcriptional ampliﬁcation, our
enhanced systems were approximately 8-fold more potent in cultured neurons
and astroglial cells and at least 8- to 12-fold more potent in the rat brain in
vivo.
Conclusions Our results demonstrate theeffectiveness ofthe transcriptional
ampliﬁcation strategy in developing viral gene delivery systems that combine
the advantages of speciﬁc cell type targeting and Tet-inducible expression.
Copyright  2008 John Wiley & Sons, Ltd.
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Introduction
The central nervous system (CNS) is a particularly
complex organ, containing not only multiple types of
neurons withdifferent and sometimes opposingfunctions,
but also oligodendrocytes, microglia and astrocytes.
Astrocytes in particular have been of increasing interest
as the extent of their roles in CNS function becomes
understood [1,2]. The existence of various types of cells
in the CNS underscores the importance of restricting
transgene expression to speciﬁed target cell types in the
brain and has stimulated extensive studies to develop
gene expression vectors with speciﬁc cellular promoters
[3–5]. In addition to directing speciﬁc gene expression,
cell-type-speciﬁc promoters may be less likely to activate
host cell defence machinery so that improved stability
of gene expression can be expected [6,7]. However, the
main limitation of brain-cell-speciﬁc promoters is their
relatively weak transcriptional activity compared with
viral promoters [8–10].
An ideal gene delivery vector system for the CNS
should also have the ability to efﬁciently control the
timing of gene expression and the amount of expressed
gene products. Among the different regulatable transgene
expression systems that have been developed, the
tetracycline-based regulatable system (Tet-system) [11]
has been the most popular tool for controlling gene
expression. There are two basic variants of the Tet-
system; one utilises the tTA transactivator (‘Tet-Off’
system) and the other the rtTA transactivator (‘Tet-
On’ system) [12,13]. In the Tet-off system, tTA binds
to the Tet-regulatable element (TRE) in the absence
of doxycycline (Dox) and initiates transcription of the
target gene from a promoter which incorporates the
minimal cytomegalovirus (CMV) core promoter. The
original TRE-based vectors suffered from disadvantages
such as high basal ‘leak’ expression and low efﬁciency of
regulation [14]. With continuous attempts to overcome
these problems, a modiﬁed TRE marketed by Clontech as
‘TRE-tight’hasbeendeveloped toachieve highinducibility
combined with undetectable levels of leak expression
[15]. This TRE-tight promoter contains a 60-bp shortened
CMV minimal promoter together with seven 19-bp tet
operator sequences positioned in an optimised manner
upstream of the TATA box [16]. However, application of
this TRE-tight system to cell-speciﬁc expression proved
to be difﬁcult: when used in combination with either the
PRSx8 promoter [5] or the GAD67 promoter [17], we
failed to achieve a sufﬁcient level of gene expression
(S. Kasparov and A. G.Teschemacher, unpublished
observation; [18,19]). The most logical explanation of
this low activity was that a high level of tTA expression
required for such a control cannot be supplied by the
standard brain-cell-speciﬁc promoters.
A dual vector adenoviral Tet-system for tetracycline-
controllable expression of transgenes in the brain was
described by Harding et al. [20]. The design had two
main features: on one hand, it was possible to control
gene expression in the brain by administering Dox into
the drinking water. On the other, physically separating
the transactivator elements from the TRE increased the
control of gene expression. In addition, this design
theoretically allows targeting of the transgene to a speciﬁc
cellular phenotype when the Tet transactivator tTA or
rtTA is placed under control of a cell-speciﬁc promoter.
Later studiesreported cell-speciﬁc Tet-off regulatable dual
adenoviral systems where tTA was expressed under the
control of neuronal- or glial-speciﬁc promoters [18,21].
However, in both instances unpotentiated cell-type-
speciﬁc promoters and the original TRE, rather than
TRE-tight, were employed. This led to low levels of tTA
expression and leak expression with appearance of the
transgenes in unsolicited cell types [4].
In order to overcome these limitations, we have
employed a relatively generalisable method, a two-
step transcriptional ampliﬁcation (TA) strategy. The
method utilises artiﬁcial transcriptional activators to
enhance transgene expression from potentially any cell-
type-speciﬁc promoter [8,22,23]. This strategy involves
cell-type-speciﬁc expression of a strong chimeric activa-
tor GAL4p65 consisting of the transactivation domain of
nuclear factor-kappaB (NFκB) p65 protein and the DNA-
binding domain of the GAL4 protein from yeast. GAL4p65
then binds to multiple Gal4-binding sites placed upstream
ofthesecondcopyofthesamecell-speciﬁc promoter,lead-
ing to a massively ampliﬁed expression of the transgene.
We hypothesised that tTA expressed using this approach
would efﬁciently control expression of TRE-tight-based
cassettes. As a proof of principle, we have tested the
two-step TA method using two relatively weak cell-type-
speciﬁc promoters. One is the 495-bp SYN promoter,
which has been extensively characterised and shown to
drive neuron-speciﬁc expression in various regions in the
brain [10,24]. The other is a human glial ﬁbrillary acidic
protein (GFAP) that drives gene expression in astrocytes
[25]. To accommodate the limited cloning capacity of
lentiviruses, we used a compact version of the standard
2.2-kb GFAP promoter made by deleting 5  nucleotides
−2163 to −758 and an internal segment from −1255
to −133. The resultant 681-bp promoter, GfaABC1D, has
expression properties in transgenic mice indistinguishable
from the 2.2-kb version (unpublished observations).
Materials and methods
Construction of lentiviral plasmids
Five lentiviral plasmids were constructed based on the
improved lentiviral shuttle vector pTYF-SW-Linker back-
bone [26]. To generate the LV-Tretight-DsRed2 shuttle
vector,theTretight-DsRed2 fragmentcontainingthemod-
iﬁed Tet-responsive promoter and the red ﬂuorescent pro-
tein (DsRed2) gene was excised from pTRE-Tight-DsRed2
(Clontech) with XhoI/NotIa n dc l o n e di n t op T Y F - S W -
Linker. The LV-1×SYN-tTA shuttle vector was obtained
by replacing the EGFP fragment in pGBS-SYN-EGFP [22]
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with tTA. To construct the LV-2×SYN-tTA shuttle vector,
tTA was ampliﬁed by polymerase chain reaction (PCR)
and ligated into SpeI/NotI sites of pTYF-2×SYN-EGFP
[22] after the EGFP fragment had been removed. The LV-
1×GfaABC1D-tTA shuttle vector was produced by replac-
ing the SYN fragment in the LV-1×SYN-tTA shuttle vector
with the GfaABC1D PCR product between the MluIa n d
BamHI sites. Three cloning steps were necessary to gen-
erate the LV-2×GfaABC1D-tTA shuttle vector. First, the
SYN promoter in pSYN-GAL4p65 [22]was replaced by the
GfaABC1D PCR product between the AseIa n dNheIs i t e s .
The plasmid was then digested with AseI, ﬁlled in with
Klenow enzyme,followedbyMluIdigestion.Thefragment
encoding the GfaABC1D promoter, GAL4p65 and SV40pA
was then isolated and cloned into EcoRV/MluI-treated
pTYF-SW linker. Finally, the NheI/blunt/XhoIf r a g m e n t
from the LV-1×GfaABC1D-tTA shuttle vector was inserted
into the resultant plasmid from the above two steps pre-
viously treated with MluI/blunt/NotI.
Production of lentiviral (LV) vectors
The LV system used in this study is derived from HIV-
1 and pseudotyped with the vesicular stomatitis virus
coat glycoprotein. LV stocks were produced by transient
co-transfection of the shuttle plasmids, the packaging
vector pNHP, and the envelope plasmid pHEF-VSVG in
HEK293FT cells. Viral concentration and titration were
carried out as described earlier [27].
Cell culture and in vitro LV vector
transduction
The in vitro transduction experiments were carried out
in a neurone-derived rat pheochromocytoma PC12 cell
line and a 1321N1 glial cell line from human brain
astrocytoma. PC12 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS) and 5%
horse serum. 1321N1 cells were cultured in DMEM
supplemented with 10% heat-inactivated FBS. The cells
were split and plated in 24-well plates at a cell density of
5 × 104/wellwith0.5 mlculturemedium.After24 h,cells
were transduced overnight with appropriate lentiviruses
in the presence of polybrene (8 µg/ml). Cells were then
washed in phosphate-buffered saline (PBS) and were
cultured in DMEM for a further 48 h. For each virus
combination, three wells were transduced.
Delivery of LV vectors into the rat
hypoglossal motor nucleus in vivo
Male Wistar rats (250–300 g) were used. All procedures
were carried out according to the Home Ofﬁce Animals
Scientiﬁc Procedures Act 1986, UK. Animals were deeply
anaesthetised with an intramuscular injection of ketamine
(60 mg/kg) and medetomidine (250 µg/kg). They were
placed in a stereotaxic head holder and the caudal
dorsal medulla was exposed through a midline incision
in the dorsal neck. A total of six microinjections of
viral vector were made bilaterally at the level of the
calamus scriptorius and 400 µm rostral and caudal to it,
300–500 µm from the midline and 450–550 µmv e n t r a l
to the dorsal surface of the medulla. The injection rate
was 0.5 µl/min and the injection needle was allowed to
remain in situ for 5 min before being slowly retracted at
theendofeachinjection.Thewoundwassutured,cleaned
and treated with antiseptic powder. Medetomidine
anaesthesia was reversed with a subcutaneous injection
of atipamezole (1 mg/kg). Animals were returned to
individual cages for recovery, and kept with normal
rat chow and drinking water ad libitum on a 12 h
light/12 h dark cycle. Seven days after injection, rats
were terminally anaesthetised (sodium pentobarbital,
100 mg/kg, intramuscularly) and perfused intracardially
with 4% formaldehyde in 0.1 M PBS (pH 7.4). Brainstems
were then removed, postﬁxed in the same ﬁxative for
2–4 h before they were placed in 20% sucrose overnight.
Serial 40 µm sections were cut on a freezing microtome
and kept in 0.1 M PBS. For quantitative analysis, three
rats from each group were used to examine the number
of DsRed2-positive cells. Four sections surrounding the
injection tract for each rat were selected randomly and
three ﬁelds from each section were used for cell counting.
Immunohistochemistry analysis
Free-ﬂoating formaldehyde-ﬁxed sections (as described
above) were washed for 20 min in 0.1 M PBS at pH
7.4 containing 0.2% Triton X-100. Sections were then
incubated overnight with a monoclonal antibody against
neuron-speciﬁc nuclear protein (NeuN) or glial ﬁbrillary
acidic protein(GFAP)(bothfrom Chemicon International,
USA; dilution 1:500) and 5% normal horse serum
(NHS) in PBS. This was followed by 4 h incubations
in biotinylated donkey-anti mouse F(ab)2 fragments
(1:500, Jackson Immunolabs, PA, USA) and 2% NHS
in PBS, then ExtrAvidin-FITC in PBS (1:1000, Sigma).
Washes were performed between incubations (PBS,
3 × 5 min), at room temperature. Sections were then
collected on gelatin-coated slides with Vectashield non-
quenching mounting medium (Vector Labs, CA, USA).
Confocal images were obtained using a Leica confocal
SP microscope. Images were taken at 1–2 µmi n t e r v a l s
throughout the thickness of the section. The two channels
(DsRed2 and FITC) were scanned separately using 488
and 543 nm excitation laser lines to avoid ‘bleed’ of
ﬂuorescence between channels and merged using Leica
software.
Statistical analysis
Unpaired t test was applied for comparisons between two
groups. The differences were considered signiﬁcant at
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p < 0.05. All values in the text and ﬁgures refer to mean
± standard deviation (SD).
Results
Construction of lentiviral (LV) vectors
Five self-inactivated HIV-derived LV vectors (Figure 1)
were constructed for this study. (1) LV-Tretight-DsRed2,
in which the DsRed2 reporter gene is under control of
the TRE-tight promoter; (2) LV-1×SYN-tTA, in which the
Tet-Off system transactivator tTA gene is driven by the
SYN promoter only; (3) LV-2×SYN-tTA, a dual expression
cassette containing SYN-driven tTA and the SYN-driven
GAL4p65 in a single backbone; (4) LV-1×GfaABC1D-tTA,
in which the tTA gene is transcribed by the GfaABC1D
promoter only; and (5) LV-2×GfaABC1D-tTA, a dual
expression cassette containing GfaABC1D-driven tTA and
the GfaABC1D-driven GAL4p65 in a single backbone.
Thus, the combinations of LV-Tretight-DsRed2 + LV-
2×SYN-tTA and LV-Tretight-DsRed2 + LV-2×GfaABC1D-
tTA constitute the TA-enhanced lentiviral neuronal- or
glial-speciﬁc Tet-regulatable systems. LV-Tretight-DsRed2
+ LV-1×SYN-tTA and LV-1×GfaABC1D-tTA, without TA,
served as controls.
In vitro analysis of gene expression
As a starting point, we tested the ‘tightness’ of the
TRE-tight element using LV-Tretight-DsRed2 in vitro.I n
the absence of Dox, transgene expression from LV-
Tretight-DsRed2(multiplicityofinfection(MOI) = 5)was
undetectableineitherneuronalPC12cells orglial 1321N1
cells, conﬁrming no leak expression of the vectors in the
tested cells (data not shown).
PC12 cells were then co-transduced with LV-Tretight-
DsRed2 and either LV-1×SYN-tTA or LV-2×SYN-tTA
while 1321N1 cells were co-transduced with LV-
Tretight-DsRed2 and either LV-1×GfaABC1D-tTA or
LV-2×GfaABC1D-tTA. The ratio between the two co-
transduced vectors was 1:1 and the total MOI for each
pair of the viral vectors was 1, 5, 15 or 25. At all of the
MOIs tested, TA-enhanced systems drove signiﬁcantly
increased DsRed2 transgene expression as compared
to the non-enhanced systems (Figures 2 and 3), with
expression from the SYN-driven TA-enhanced system
being increased approximately 8-fold (at MOIs of 5,
15 and 25) (Figure 3A) and expression from the
GfaABC1D-driven TA-enhanced system being increased
approximately 7-fold at MOIs of 5, 15 and 25 (Figure 3B).
Therefore, the extent of enhancement was similar across
a wide range of MOIs. Expression of DsRed2 in PC12 and
1321N1 cells was completely inhibited in the continuous
presence of Dox (2 µg/ml) (Figures 2c and 2h) or in the
absence of Dox for 2 days followed by Dox treatment
for 4 days (Figures 2e and 2j). The inhibition of gene
expression resulting from Dox treatment for 2 days
(Figures 2c and 2h) could be restored to the uninhibited
levels by cell culturing in the absence of Dox for 4 days
(cf. Figures 2b and 2gto 2d and 2j).These results indicate
that TA enhancement potentiates tTA/TRE-tight-driven
transgene expression without compromising its sensitivity
to Dox. To investigate the cell-type speciﬁcity of the TA-
enhanced system in vitro, we co-transduced PC12 and
1321N1 cells with LV-Tretight-DsRed2/LV-2×GfaABC1D-
tTA and LV-Tretight-DsRed2/LV-2×SYN-tTA, respectively
(molar ratio 1:1; MOI 5) in a separate experiment.
No gene expression was observed from both cell lines
Figure 1. Schematic drawing of lentiviral vectors used in this study. LTR, lentiviral long terminal repeat; Tretight, a modiﬁed
tetracycline-responsive promoter derived from pTRE-tight-DsRed2 (Clontech); DsRed2, red ﬂuorescent protein; 5×GAL4BS, ﬁve
tandem GAL4 binding sites; SYN, human synapsin 1 promoter; GfaABC1D, a compact glial ﬁbrillary acidic protein promoter;
GAL4p65, a chimeric transactivator consisting of a part of the transactivatin domain of the murine NF-κB p65 protein fused to the
DNA-binding domain of the GAL4 protein from yeast; tTA, tetracycline-controlled transactivator protein
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(data not shown) indicating that the neuronal and glial
characteristics of the SYN and the GfaABC1Dp r o m o t e ri n
the TA-enhanced system were well retained.
In vivo analysis of gene expression
To assess the levels of gene expression mediated by
our lentiviral systems in the CNS in vivo,d i f f e r e n t
combinationsofvectors were injected intothehypoglossal
motor nucleus of adult rats. All viral combinations were
injected at a 4:1 ratio between the virus encoding
the transactivator and the virus encoding the TRE-
tight response element. Compared to the controls
Figure 2. DsRed2 transgene expression in vitro in neuronal
PC12 (a–e) and astroglial 1321N1 (f–j) cells. Cells were
transduced with LV-Tretight-DsRed2 and either LV-1×SYN-tTA
(a), LV-2×SYN-tTA (b, c, d, e), LV-1×GfaABC1D-tTA (f),
or LV-2×GfaABC1D-tTA (g, h, i, j). The ratio between the
trasactivator and Tre viruses was 1:1, with a total viral MOI
of 5 per well. (a, b, f, g) Forty-eight hours after transduction
without Dox treatment. DsRed2 expression was observed in all
four groups. (c, h) Forty-eight hours after transduction in the
presence of Dox. DsRed2 expression was completely repressed.
(d, i) Dox was present for 48 h after transduction followed by
a change to Dox-free medium and culturing for 4 more days.
Repressed DsRed2 gene was retrieved maximally. (e, j) Dox
was absent for 48 h after transduction followed by a change to
Dox-containing medium and culturing for 4 more days. Note
DsRed2 expression was completely abolished
(Figures 4a and 4f), we observed approximately 12-
and 8-fold increases in the number of DsRed2-positive
cells in the rats injected with LV-Tretight-DsRed2/LV-
2×SYN-tTA and LV-Tretight-DsRed2/LV-2×GfaABC1D-
tTA, respectively (Figures 4b, 4g; 5A and 5B). The
cells from groups injected with TA-containing vectors
appeared much brighter, although this parameter was not
quantiﬁed in this study. Please note that the density of
DsRed2-positive astrocytes using LV-Tretight-DsRed2/LV-
2×GfaABC1D-tTA (Figure 5B) was higher than neurones
using LV-Tretight-DsRed2/LV-2×SYN-tTA (Figure 5A).
This might reﬂect higher numbers of astrocytes compared
to neurons in vivo but also be due to the higher
transcriptional efﬁciency of the GfaABC1D promoter than
that of the SYN promoter, because similar results were
obtained in vitro (Figure 3).
To test the in vivo inducibility of gene expression, rats
were injected with LV-Tretight-DsRed2/LV-2×SYN-tTA
or LV-Tretight-DsRed2/LV-2×GfaABC1D-tTA and given
drinking water in three different ways: (I) drinking water
supplemented with 5% sucrose containing 2 mg/ml Dox
for 7 days; (II) drinking water supplemented with 5%
sucrose containing 2 mg/ml Dox for 7 days followed
by normal drinking water for another 7 days; and (III)
normal drinking water for 7 days followed by drinking
water containing 2 mg/ml Dox in 5% sucrose for another
7 days. In group I, DsRed2 transgene expression was
completely repressed by Dox (Figures 4c and 4h). In
group II, DsRed2 expression became evident 4 days after
the removal of Dox (data not shown) and reached the
levels similar to those in the rats injected with the viruses
but not treated with Dox by day 7 (Figures 4d and 4i).
In group III, repression of DsRed2 expression became
evident 4 days after the administration of Dox (data not
shown) and only very few positive cells could be observed
by day 7, most likely due to the very slow degradation
of the pre-synthesised DsRed2 (Figures 4e and 4j). These
results demonstrate efﬁcient and reversible modulation of
the transgene expression in vivo.F u r t h e r m o r e ,c o n s i s t e n t
with our previous observations [22], we did not detect
evidence of local inﬂammation, cell death or other
pathology that could indicate toxicity of the TA-treated
binary Tet systems.
Cell-type speciﬁcity
One of the critical issues in applying the TA strategy
using cell-type-speciﬁc promoters is whether their cell-
type speciﬁcity is preserved. To address this issue,
we performed immunohistochemistry using antibodies
against neuron-speciﬁc nuclear protein (NeuN) to
visualise neurons and antibodies against glial ﬁbrillary
acidic protein (GFAP) to visualise astrocytes (Figure 6).
Essentially, all DsRed2-positive cells in the LV-Tretight-
DsRed2/LV-2×SYN-tTA-injected rats wereNeuN-positive,
whereas none stained positively for GFAP, indicating
that the transgene was expressed exclusively in neurons.
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Figure 3. Quantiﬁcation of in vitro transgene expression from transcriptional ampliﬁcation-enhanced Tet-Off regulatory systems at
MOIs of 1, 5, 15 and 25. (A) SYN-containing system in neuronal PC12 cells. (B) GfaABC1D-containing system in astroglial 1321N1
cells. Numbers of DsRed2-positive cells per ﬁeld of view were counted under 100× magniﬁcation. Six ﬁelds were selected randomly
for cell counting. The error bars indicate the standard deviations
Conversely,inLV-Tretight-DsRed2/LV-2×GfaABC1D-tTA-
injected rats, the bulk of DsRed2-positive cells were
positively stained with GFAP, while in no case was
there co-localisation of DsRed2 and NeuN signals,
demonstrating the restricted expression of DsRed2 to
glial cells.
Discussion
An expression system that can target speciﬁc cell
types in the CNS and be tightly controlled by a
drug would greatly facilitate neurobiological research
and gene therapy applications. Tet-regulatable gene
expression systems have the potential for regulatable
targeted gene expression if coupled with cell-type-speciﬁc
promoters. However, the application of tissue- or cell-
type-speciﬁc promoters to target transgene expression
is often hampered by their relatively weak activity.
This disadvantage also compromised their use in the
context of TRE-tight-based expression systems. We have
previously demonstrated that TA is a potent strategy to
augment transgene expression from two neuron-speciﬁc
promoters in the brain in vivo without compromising their
cell speciﬁcity [22]. In view of the modular structure
of the strategy, we reasoned that it should also work
well for the enhancement of tTA expression using well-
characterised but fairly weak mammalian promoters, such
as SYN and GfaABC1D promoters. In the present study,
we incorporated a TA step to potentiate tTA expression
driven bythese twocellular promoters. Toourknowledge,
this study is the ﬁrst to incorporate the TA strategy in
a tetracycline-regulatable cell-speciﬁc expression system.
Transgene expression from this system is characterised by
three beneﬁcial features: cell-type-speciﬁc expression, a
high level of expression and tight regulation by Dox.
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Figure 4. DsRed2 transgene expression in the hypoglossal motor
nucleus of the rat brain. LV-Tretight-DsRed2 was injected
with either LV-1×SYN-tTA (a), LV-2×SYN-tTA (b, c, d, e),
LV-1×GfaABC1D-tTA (f), or LV-2×GfaABC1D-tTA (g, h, i, j).
The ratio between the transactivator-expressing and Tre viruses
was 4:1 and a total of 6 × 106 IU of viruses was injected
per rat. (a, b, f, g) Seven days after injection and without
Dox treatment. DsRed2 expression was observed in all four
groups. (c, h) Virus-injected rats drank Dox-containing water
for 7 days. DsRed2 expression was completely repressed. (d,
i) Dox treatment for the ﬁrst 7 days after injection followed
by Dox-free water for another 7 days. Repressed DsRed2 gene
was retrieved maximally. (e, j) Dox-free water for the ﬁrst
7 days after injection followed by Dox-containing water for
another 7 days. Note DsRed2 expression was almost completely
abolished
The construction of the recombinant transcriptional
activator, GAL4p65, is based on the well-identiﬁed
modular structures of two transcriptional factors, the
murine NFκB p65 and the yeast GAL4. NFκBi sa
group of dynamically modulated dimeric transcription
factors, with the p50/p65 dimer being the most common
protein complex regulating expression of mammalian
genes across species, cell types and developmental stages.
In the CNS, NFκB has a constitutive and relatively high
level of activity in neurons [28,29] and plays a crucial
Figure 5. Quantiﬁcation of in vivo transgene expression from
TA-enhanced Tet-Off regulatory systems. Viruses were injected
into the rat brain as described, see legend for Figure 4.
(A) SYN-based system. (B) GfaABC1D-based system. Seven days
after injection, numbers of DsRed2-positive cells per view of
ﬁeld were counted under 400× magniﬁcation. For each rat, four
40 µm coronal sections surrounding the injection tract and three
ﬁelds in each section were selected randomly for cell counting
(n = 3r a t sp e rg r o u p ) .∗, ∗∗p < 0.05 and 0.01, respectively
role in neuronal survival in a variety of physiological
and pathological settings [29–31]. NFκB also plays a
crucial role in regulating inﬂammatory gene expression
in glial cells [32]. The high efﬁciency of NFκBi nn e u r o n s
and glial cells indicates that co-activators and regulators
required for NFκB transcriptional activity are present in
these two groups of cells. The most active part of the
transcription activation domain of NFκBp 6 5i sl o c a t e d
between amino acids 364 and 549 [33], which have
been used for generation of the mammalian two hybrid
system by Stratagene. The yeast GAL4 gene expression
system is one of the most widely studied eukaryotic
transcriptional regulatory systems. Of the 881 amino
acids that constitute the transcriptional activator of GAL4,
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Figure 6. The speciﬁcity of TA-enhanced Tet-Off regulatory systems. Viruses were injected into the rat brain (see also legend
for Figure 4). Seven days after injection, brain tissues were collected. Frozen coronal transverse 40 µm sections were cut and
immunostained against NeuN to visualise neurons and against GFAP to visualise astroglial cells
the fragment compromising amino acids 1–147 contains
the DNA-binding domain and also acts as a nuclear
localisation signal [34]. In this study, we fused the
transcriptional activation domain of murine NFκBp 6 5
(amino acids 364–550) to the DNA-binding domain
of GAL4 (amino acids 1–147) to form GAL4p65. As
demonstrated here, the generated chimeric protein works
as a strong artiﬁcial transcriptional factor and provides
signiﬁcantly improved transgene expression.
In assessing the inducibility of our systems, an
important consideration is that the dynamics of DsRed2
disappearance from the living cells will be strongly
affected by the half-life of this protein while its
‘appearance’ will be affected by the speed of ﬂuorophore
maturation. Although we could not ﬁnd the relevant
information for DsRed2, its close analogue DsRed1
is believed to be very stable with a half-life of
more than 4 days [35]. In vitro experiments showed
that transgene expression could be induced rapidly
(4 days) following Dox withdrawal (Figures 2d and 2i).
Furthermore, transgene expression could be repressed
completely 4 days after the re-administration of Dox. The
in vitro kinetics of gene expression of the Tet-Off system
as described above are in agreement with previous studies
[11,18]. In vivo DsRed2 expression could also be switched
on or off reversibly simply by adding or removing Dox
from the drinking water. However, the time taken for
transgene expression (∼7 days) to be turned on or off
following the withdrawal or re-administration of Dox was
signiﬁcantly longer in vivo than in vitro. The relatively
long in vivo half-life of Dox and its likely accumulation
and release from tissues are the probable causes of these
deferences [36,37].
To achieve well-preserved cell-type speciﬁcity, we
chose to place the elements required for regulated
expression, i.e, the TRE-tight element and the tTA, into
two separate viral vectors. There is evidence suggesting
that incorporating the transactivator and TRE promoter
into the same vector decreases the efﬁciency of expression
control and results in reduced ability to regulate gene
expression and/or increased basal leakiness from the TRE
promoter [19,21]. We used ratios of 1:1 and 1:4 of virus
of the TRE/DsRed2 reporter virus to the virus encoding
the transactivator tTA. For in vitro experiments, a 1:1
ratio mediated effective transgene expression with no
loss of regulatability. However, for in vivo experiments
the ratio was changed to 1:4 as it gave better results
than a 1:1 ratio (data not shown). Previous studies
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have reported varying results for the transactivator gene
to the TRE/reporter gene ratio that produces optimal
induction properties. While some authors found that a
1:1 tTA/TRE ratio gave optimal induction and negligible
background expression, others found that higher or lower
ratios were optimal [19,21,38–40]. Multiple variables
could contribute to these different ﬁndings, including the
promoters used for the expression of the transactivator,
the cell lines, or in vivo target organ, the delivery system
used and the sensitivity of the detection method for
levels of transgene expression. It is therefore important
to establish the optimal conditions for each application or
target organ.
Placing tTA and TRE-tight into separate vectors also
has the additional advantage of extending the use of a
given construct by matching it with different partners.
One particularly exciting application of this strategy
is cell-speciﬁc targeting of TRE-tight-controlled miRNA-
expressing cassettes for gene knock-down, as described
by Stegmeier et al. [41]. On the other hand, a potential
drawback of the binary system is that only the cells
dually transduced with both viral vectors will express the
desired transgene. The apparent inability to efﬁciently co-
transduce different virions into the same cell efﬁciently
has been attributed to viral interference [42], which
can occur between two dissimilar or homologous viruses
[43,44]. The mechanism underlying the interference is
unclear, although it might occur at the level of viral
entry through receptor down-regulation or the ability of
one virus to inhibit the replication of a second virus
within the same cell [45–47]. However, successful co-
transduction of both dividing and non-dividing cells
with two VSV-G-pseudotyped HIV-1 vectors is possible
[48]. The efﬁciency of the co-transduction was directly
proportional to the individual transduction efﬁciencies
obtained with single vectors. It was hypothesised that
VSV-Gpseudotypingwouldprecludereceptorinterference
based on the observation that VSV-G-mediated entry is
receptor-independent [45,49]. We did not speciﬁcally
quantify the co-transduction efﬁciency in this study.
Since TRE-tight-driven DsRed2 expression was essentially
undetectable in the absence of a second tTA-expressing
vector, it is clear that our binary VSV-G-pseudotyped
LV vectors successfully co-tranduced both neuronal and
astroglial cells in vitro and in vivo.
In conclusion, we present a new strategy to over-
come the problem of insufﬁcient activity of cell-speciﬁc
promoters in the context of TRE-tight gene expression
vectors. This represents a signiﬁcant step towards devel-
oping effective gene delivery systems that can be used for
diverse applications, ranging from basic biomedical inves-
tigations to cell-type-speciﬁc gene therapy of numerous
brain disorders.
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